返回 A A A Font Size Receive E-mail Alerts Press Releases

Foxtrot™ NC PTCA Gains Regulatory Approval in Malaysia

[2018-03-29] 

Kuala Lumpur, Malaysia – Shanghai MicroPort Medical (Group) Co., ("MicroPort®") recently gained the regulatory approval from Malaysia's Medical Device Authority ("MDA") for its in-house developed Foxtrot™ NC PTCA Balloon Catheter ("Foxtrot™ NC").
 
Foxtrot™ NC is indicated for pre-dilation as well as post-dilation. The shaft has a combination of single lumen and dual lumens tubing and is made from high polymer material with high pressure resistance. Foxtrot™ NC is a low-compliant balloon catheter and has a short deflation time. Super hydrophilic coating allows the catheter to move freely in vessels and reach the narrow lesion area smoothly. Two radiopaque markers aid in the positioning of the balloon under fluoroscopy during procedures. Foxtrot™ NC has excellent crossability, trackability and pushability. Foxtrot™ NC approved in Malaysia has a total of 60 specifications, covering 10 diameters (2.2mm to 5.0mm) and six lengths (6mm, 8mm, 10mm, 12mm, 15mm and 20mm).
 
Previously, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Foxtrot™ Pro PTCA Balloon Catheter were approved to enter the Malaysia market. As Foxtrot™ NC also gained the regulatory approval, it will further diversify MicroPort®'s cardiovascular product line in Malaysia and offer more comprehensive solutions for local patients. Meanwhile, it is expected to help MicroPort® further consolidate and expand its market share of cardiovascular products in Malaysia and other overseas markets.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:Firehawk® Gains Regulatory Approval in Myanmar
[Next]:MicroPort® EP Attends the 10th VAS-CHINA